Abstract Number: 558 • 2012 ACR/ARHP Annual Meeting
Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Background/Purpose: Axial spondyloarthritis (axSpA) is a form of spondyloarthritis (SpA) that includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), as defined by the…Abstract Number: 363 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry
Background/Purpose: : Despite treatment with tumour necrosis factor inhibitors (TNFi) some rheumatoid arthritis (RA) patients progress radiographically in randomised controlled trials and observational cohorts (1).…Abstract Number: 1848 • 2012 ACR/ARHP Annual Meeting
Impact of Biologics On Total Knee Replacement and Total Hip Replacement Rates in Rheumatoid Arthritis Patients: Results From US Marketscan Database
Background/Purpose: Joint replacement surgery patterns continue to change in patients with rheumatoid arthritis (RA), possibly reflecting the widespread adoption of disease modifying antirheumatic drugs, earlier…Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…Abstract Number: 173 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Background/Purpose: Background: Current recommendations for latent tuberculosis infection (LTB) screening and treatment in patients eligible for anti-TNF agents are not well established in endemic regions.…Abstract Number: 1835 • 2012 ACR/ARHP Annual Meeting
Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity
Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since…Abstract Number: 1330 • 2012 ACR/ARHP Annual Meeting
High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
High BMI is associated with decreased response to initial combination therapy in recent onset RA patients Background/Purpose: A diminished response to combination treatment with a fixed…Abstract Number: 543 • 2012 ACR/ARHP Annual Meeting
Wnt Pathway Inhibitors in Patients with Psoriatic and Rheumatoid Arthritis Treated with Anti-TNF Therapy
Background/Purpose: Both rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterised by bone erosion but aberrant bone formation is also a feature in PsA. Wnt…Abstract Number: 132 • 2012 ACR/ARHP Annual Meeting
FDG-PET Evaluation of Axillary Lymph Nodes and Large Joints of Patients with Rheumatoid Arthritis Treated with Anti-TNF Drugs
Background/Purpose: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to image synovial inflammation in patients with rheumatoid arthritis (RA). The development of molecular…Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…Abstract Number: 546 • 2012 ACR/ARHP Annual Meeting
The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients
Background/Purpose: Spondyloarthropathies (SpAs) encompass a heterogeneous group of diseases that primarily affect the axial skeleton and entheses. Although anti-TNF drugs have proven to be effective…Abstract Number: 2664 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Background/Purpose : Anti-TNF therapy has become a standard therapeutic strategy for treatment of patients with rheumatoid arthritis (RA). A validated multi-biomarker disease activity algorithm (MBDA) blood…Abstract Number: 1818 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
Background/Purpose: Anti-TNFα drugs are associated with an increased risk of tuberculosis (TB) and several recommendation sets for latent tubercular infection (LTBI) detection and TB reactivation…